Company Quick10K Filing
Quick10K
Inrad Optics
10-Q 2019-09-30 Quarter: 2019-09-30
10-Q 2019-06-30 Quarter: 2019-06-30
10-Q 2019-03-31 Quarter: 2019-03-31
10-K 2018-12-31 Annual: 2018-12-31
10-Q 2018-09-30 Quarter: 2018-09-30
10-Q 2018-06-30 Quarter: 2018-06-30
10-Q 2018-03-31 Quarter: 2018-03-31
10-K 2017-12-31 Annual: 2017-12-31
10-Q 2017-09-30 Quarter: 2017-09-30
10-Q 2017-06-30 Quarter: 2017-06-30
10-Q 2017-03-31 Quarter: 2017-03-31
10-K 2016-12-31 Annual: 2016-12-31
10-Q 2016-09-30 Quarter: 2016-09-30
10-Q 2016-06-30 Quarter: 2016-06-30
10-Q 2016-03-31 Quarter: 2016-03-31
10-K 2015-12-31 Annual: 2015-12-31
10-Q 2015-09-30 Quarter: 2015-09-30
10-Q 2015-06-30 Quarter: 2015-06-30
10-Q 2015-03-31 Quarter: 2015-03-31
10-K 2014-12-31 Annual: 2014-12-31
10-Q 2014-09-30 Quarter: 2014-09-30
10-Q 2014-06-30 Quarter: 2014-06-30
10-Q 2014-03-31 Quarter: 2014-03-31
10-K 2013-12-31 Annual: 2013-12-31
8-K 2019-06-19 Shareholder Vote
8-K 2019-05-16 Officers, Exhibits
8-K 2019-05-15 Regulation FD, Exhibits
8-K 2018-10-01 Officers
8-K 2018-06-27 Shareholder Vote
CQH Cheniere Energy Partners Holdings 6,956
TMDX Transmedics 505
NMUS Nemus Bioscience 38
MXSG Mexus Gold 19
VRCP Virtual Crypto Technologies 17
IFNY Infinity Energy Resources 0
C130 Ministry Partners Investment Company 0
WUC Western Uranium 0
MRCZ Mikrocoze 0
MTLQQ Motors Liquidation 0
INRD 2019-09-30
Note 1- Summary of Significant Accounting Policies
Note 2 - Revenue
Note 3 - Equity Compensation Program and Stock Based Compensation
Note 4 - Stockholders' Equity
Note 5 - Related Party Transactions
Note 6 - Other Long Term Notes
Note 7 - Lease Amendment
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3.Quantitative and Qualitative Disclosures About Market Risk
Item 4.Controls and Procedures
Part II.Other Information
Item 1.Legal Proceedings
Item 1A.Risk Factors
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds
Item 3.Defaults Under Senior Securities
Item 4.Mine Safety Disclosures
Item 5.Other Information
Item 6.Exhibits
EX-31.1 tm1919532d1_ex31-1.htm
EX-31.2 tm1919532d1_ex31-2.htm
EX-32.1 tm1919532d1_ex32-1.htm
EX-32.2 tm1919532d1_ex32-2.htm

Inrad Optics Earnings 2019-09-30

INRD 10Q Quarterly Report

Balance SheetIncome StatementCash Flow

10-Q 1 tm1919532-1_10q.htm FORM 10-Q

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

  x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the quarterly period ended September 30, 2019

 

or

 

  ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the transition period from ___________ to ___________

 

Commission File Number 0-11668

 

INRAD OPTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

New Jersey   22-2003247
State or Other Jurisdiction of
Incorporation or Organization
  I.R.S. Employer Identification No.
     
181 Legrand Avenue, Northvale, NJ   07647
Address of Principal Executive Offices   Zip Code

 

(201) 767-1910  
Registrant’s Telephone Number, Including Area Code  
    
    

Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  x     No ¨

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes x     No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨ Accelerated filer  ¨
Non-accelerated filer  x Smaller reporting company  x
  Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes ¨    No x

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

 Title of each class   Trading Symbol(s)   Name of each exchange on
which registered
None   None   None

 

The number of shares of the registrant’s common stock outstanding, $0.01 par value, as of November 14, 2019, was 13,735,177.

 

 

 

 

 

INRAD OPTICS, INC AND SUBSIDIARIES

 

INDEX

 

Part I. CONDENSED FINANCIAL INFORMATION  
     
Item 1. Condensed Consolidated Financial Statements:  
     
  Condensed consolidated balance sheets as of September 30, 2019 (unaudited) and December 31, 2018 1
     
  Condensed consolidated statements of operations for the three and nine months ended September 30, 2019 and 2018 (unaudited) 2
     
  Condensed consolidated statements of shareholders equity for the three months and nine months ended September 30, 2019 and 2018 (unaudited) 3
     
  Condensed consolidated statements of cash flows for the nine months ended September 30, 2019 and 2018 (unaudited) 4
     
  Notes to condensed consolidated financial statements (unaudited) 5
     
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 12
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 15
     
Item 4. Controls and Procedures 15
     
Part II. OTHER INFORMATION 16
     
Item 1. Legal Proceedings 16
     
Item 1A. Risk Factors 16
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 16
     
Item 3. Defaults upon Senior Securities 16
     
Item 4. Mine Safety Disclosures 16
     
Item 5. Other Information 16
     
Item 6. Exhibits 16
     
Signatures   17

 

 

 

 

INRAD OPTICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

 

   September 30,   December 31, 
   2019   2018 
   (Unaudited)     
Assets          
Current assets:          
Cash and cash equivalents  $812,309   $1,185,553 
Accounts receivable (net of allowance for doubtful accounts of $15,000 in 2019 and 2018)   1,134,415    1,296,487 
Inventories, net   2,973,097    3,015,883 
Other current assets   117,367    180,893 
Total current assets   5,037,188    5,678,816 
           
Plant and equipment:          
Plant and equipment,  at cost   14,988,285    14,696,966 
Less: Accumulated depreciation and amortization   (14,257,044)   (14,069,880)
Total plant and equipment   731,241    627,086 
Precious metals   561,909    562,347 
Intangible assets, net   21,964    32,156 
Lease right-of-use   754,653    - 
Other assets   23,149    32,020 
Total Assets  $7,130,104   $6,932,425 
           
Liabilities and Shareholders' Equity          
Current liabilities:          
Current portion of other long term notes  $12,960   $12,960 
Accounts payable and accrued liabilities   807,636    835,015 
Contract liabilities   794,034    772,927 
Current portion of lease obligation   264,297    - 
Total current liabilities   1,878,927    1,620,902 
           
Related party convertible notes payable   2,500,000    2,500,000 
           
Other long term notes, net of current portion   173,763    244,781 
Lease obligation, net of current portion   490,356    - 
Total liabilities   5,043,046    4,365,683 
           
Commitments          
           
Shareholders' equity:          
Common stock: $.01 par value; 60,000,000 authorized shares; 13,735,177 shares issued at September 30, 2019, and 13,636,988 shares issued at December 31, 2018   137,353    136,371 
Capital in excess of par value   19,245,969    19,055,615 
Accumulated deficit   (17,281,314)   (16,610,294)
    2,102,008    2,581,692 
Less - Common stock in treasury, at cost (4,600 shares)   (14,950)   (14,950)
Total shareholders' equity   2,087,058    2,566,742 
Total Liabilities and shareholders' equity  $7,130,104   $6,932,425 

 

See Notes to Condensed Consolidated Financial Statements (Unaudited)

 

1

 

 

INRAD OPTICS, INC AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

   Three Months Ended September 30,   Nine Months Ended September 30, 
   2019   2018   2019   2018 
Total revenue  $2,223,751   $2,788,863   $7,444,434   $8,814,767 
                     
Cost and expenses:                    
Cost of goods sold   1,870,260    1,862,879    5,999,190    6,459,987 
Selling, general and administrative expenses   608,868    579,254    2,000,185    1,648,325 
    2,479,128    2,442,133    7,999,375    8,108,312 
                     
Income (loss) from operations   (255,377)   346,730    (554,941)   706,455 
Other expense:                    
Interest expense-net   (38,298)   (40,015)   (115,642)   (119,185)
Loss on exchange of precious metals   -    -    (438)   (2,288)
    (38,298)   (40,015)   (116,080)   (121,473)
                     
Income (loss) before income taxes   (293,675)   306,715    (671,021)   584,982 
                     
Income tax (provision) benefit   -    -    -    - 
                     
Net income (loss)  $(293,675)  $306,715   $(671,021)  $584,982 
                     
Net (loss) income per common share - basic  $(0.02)  $0.02   $(0.05)  $0.04 
                     
Net (loss) income per common share - diluted  $(0.02)  $0.02   $(0.05)  $0.04 
                     
Weighted average shares outstanding - basic   13,735,177    13,627,888    13,658,808    13,541,331 
                     
Weighted average shares outstanding - diluted   13,735,177    13,992,925    13,658,808    13,921,616 

 

See Notes to Condensed Consolidated Financial Statements (Unaudited)

 

2

 

 

INRAD OPTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

(Unaudited)

 

           Capital in           Total 
   Common Stock   excess of   Accumulated   Treasury   Shareholders' 
   Shares   Amount   par value   Deficit   Stock   Equity 
Balance, January 1, 2018   13,521,200   $135,213   $18,882,086   $(17,316,902)  $(14,950)  $1,685,447 
401K contribution   -    -    -    -    -    - 
Stock-based compensation expense   -    -    13,035    -    -    13,035 
Net income March 31, 2018   -    -    -    264,163    -    264,163 
Balance, March 31, 2018   13,521,200   $135,213   $18,895,121   $(17,052,739)  $(14,950)  $1,962,645 
                               
401K contribution   111,288    1,113    91,667    -    -    92,780 
Stock-based compensation expense   -    -    12,965    -    -    12,965 
Net income June 30, 2018   -    -    -    14,104    -    14,104 
Balance, June 30, 2018   13,632,488   $136,326   $18,999,753   $(17,038,635)  $(14,950)  $2,082,494 
                               
401K contribution   -    -    -    -    -    - 
Stock-based compensation expense   -    -    27,192    -    -    27,192 
Net income September 30, 2018   -    -    -    306,715    -    306,715 
Balance, September 30, 2018   13,632,488   $136,326   $19,026,945   $(16,731,920)  $(14,950)  $2,416,401 

 

           Capital in           Total 
   Common Stock   excess of   Accumulated   Treasury   Shareholders' 
   Shares   Amount   par value   Deficit   Stock   Equity 
Balance, January 1, 2019   13,636,988   $136,371   $19,055,615   $(16,610,294)  $(14,950)  $2,566,742 
401K contribution   -    -    -    -    -    - 
Stock-based compensation expense   -    -    29,375    -    -    29,375 
Net income (loss) March 31, 2019   -    -    -    (36,135)   -    (36,135)
Balance, March 31, 2019   13,636,988   $136,371   $19,084,990   $(16,646,429)  $(14,950)  $2,559,982 
                               
401K contribution   98,189    982    92,605    -    -    93,587 
Stock-based compensation expense   -    -    33,343    -    -    33,343 
Net income (loss) June 30, 2019   -    -    -    (341,210)   -    (341,210)
Balance, June 30, 2019   13,735,177   $137,353   $19,210,938   $(16,987,639)  $(14,950)  $2,345,702 
                               
401K contribution   -    -    -    -    -    - 
Stock-based compensation expense   -    -    35,031    -    -    35,031 
Net income September 30, 2019   -    -    -    (293,675)   -    (293,675)
Balance, September 30, 2019   13,735,177   $137,353   $19,245,969   $(17,281,314)  $(14,950)  $2,087,058 

 

See Notes to Condensed Consolidated Financial Statements (Unaudited)

 

3

 

 

INRAD OPTICS, INC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   Nine Months Ended 
   September 30, 
   2019   2018 
Cash flows from operating activities:          
Net income (loss)  $(671,021)  $584,982 
           
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities          
Depreciation and amortization   197,356    210,502 
(Gain) loss on exchange of precious metals   438    2,288 
401K common stock contribution - non cash item   93,587    92,780 
Stock based compensation   97,750    53,192 
Changes in operating assets and liabilities:          
Accounts receivable   162,072    (497,898)
Inventories, net   42,787    322,713 
Other current assets   63,525    1,201 
Other assets   8,870    13,246 
Accounts payable and accrued liabilities   (27,378)   (483,067)
Contract liabilities   21,107    (69,225)
Total adjustments and changes   660,114    (354,268)
Net cash (used in) provided by operating activities   (10,907)   230,714 
           
Cash flows from investing activities:          
Capital expenditures   (291,320)   (130,075)
Purchase of precious metals   -    (875)
Net cash (used in) investing activities   (291,320)   (130,950)
           
Cash flows from financing activities:          
Principal payments on notes payable-other   (71,017)   (9,308)
Net cash (used in)  financing activities   (71,017)   (9,308)
           
Net (decrease) in cash and cash equivalents   (373,244)   90,456 
           
Cash and cash equivalents at beginning of period   1,185,553    799,953 
           
Cash and cash equivalents at end of period  $812,309   $890,409 
           
Supplemental disclosure of cash flow information:          
Interest paid  $119,556   $105,490 
Income taxes paid  $-   $- 
Significant non-cash activities:          
Lease right-of-use asset  $819,622   $- 

 

See Notes to Condensed Consolidated Financial Statements (Unaudited)

 

4

 

 

INRAD OPTICS, INC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 1- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements include the accounts of Inrad Optics, Inc. and its subsidiaries (collectively, the “Company”).  All significant intercompany balances and transactions have been eliminated.

 

The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.  In the opinion of management, all adjustments of a normal recurring nature considered necessary for a fair presentation have been included.  The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the full fiscal year.  For further information, refer to the consolidated financial statements and accompanying footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

 

In preparing these unaudited condensed consolidated financial statements, the Company has evaluated events and transactions for potential recognition or disclosure through the date the unaudited condensed consolidated financial statements were issued.

 

Management Estimates

 

These unaudited condensed consolidated financial statements and related disclosures have been prepared in conformity with U.S. GAAP, which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses reported in those financial statements. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate.  As future events and their effects cannot be determined with precision, actual results could differ significantly from those estimates and assumptions.  Significant changes, if any, in those estimates resulting from continuing changes in the economic environment will be reflected in the consolidated financial statements in future periods.

 

Accounts Receivable

 

Accounts receivable are carried at net realizable value, net of write-offs and allowances. The Company establishes an allowance for doubtful accounts based on estimates as to the collectability of accounts receivable. Management specifically analyzes past-due accounts receivable balances and, additionally, considers bad debt history, customer credit-worthiness, current economic trends and changes in customer payment terms when evaluating the adequacy of the allowance for doubtful accounts. Uncollectible accounts receivable are written-off when it is determined that the balance will not be collected. Reserves for uncollectible accounts receivable are recorded as part of selling, general and administrative expenses in the Consolidated Statements of Operations, and were $15,000 at September 30, 2019.

 

Inventories

 

Inventories are stated at the lower of cost (first-in-first-out basis) and net realizable value. The Company records a reserve for slow moving inventory as a charge against earnings for all products identified as surplus, slow-moving or discontinued. Excess work-in-process costs are charged against earnings whenever estimated costs-of-completion exceed unbilled revenues.

  

Inventories are comprised of the following and are shown net of inventory reserves of $2,403,000 and $2,486,000 at September 30, 2019 and December 31, 2018, respectively:

 

5

 

 

   September 30,   December 31, 
   2019   2018 
   (Unaudited)     
    (in thousands) 
Raw materials  $1,256   $1,143 
Work in process, including manufactured parts and components   1,190    1,389 
Finished goods   527    484 
   $2,973   $3,016 

 

Income Taxes

 

The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect in the year in which the differences are expected to reverse.

 

In evaluating the Company’s ability to recover deferred tax assets in future periods, management considers the available positive and negative factors, including the Company’s recent operating results, the existence of cumulative losses and near term forecasts of future taxable income consistent with the plans and estimates that management uses to manage the underlying business. A significant piece of objective negative evidence evaluated was the cumulative loss incurred by the Company over the three year period ended December 31, 2018. Such objective evidence limits the ability to consider other subjective evidence such as our projections for future growth.

 

On the basis of this evaluation as of September 30, 2019, the Company’s management concluded that it is more likely than not that the Company will not be able to realize any portion of the benefit on the net deferred tax balance of $3,366.000 and therefore the Company continues to maintain a valuation allowance for the full amount of the net deferred tax balance. When sufficient positive evidence exists, the Company’s income tax expense will be charged with the increase or decrease in its valuation allowance. An increase or reversal of the Company’s valuation allowance could have a significant negative or positive impact on the Company’s future earnings.

  

For the three and nine months ended September 30, 2019, the Company did not record a current provision for either state tax or federal tax due to the losses incurred for both income tax and financial reporting purposes.

 

For the three and nine months ended September 30, 2018, the Company did not record a current provision for income taxes due to the availability of net operating loss carryforwards to offset taxable income for both federal and state tax purposes.

 

Net Income (Loss) per Common Share

 

Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares and common stock equivalents outstanding, calculated on the treasury stock method for options, stock grants and warrants using the average market prices during the period, including potential common shares issuable upon conversion of outstanding convertible notes, except if the effect on the per share amounts is anti-dilutive.

 

For the three and nine months ended September 30, 2019, all common stock equivalents were excluded from the computation of diluted net loss per share because their effect is anti-dilutive. This included 2,500,000 common shares and 1,875,000 common shares from warrants issuable upon conversion of outstanding related party convertible notes. In addition, 1,208,367 common stock options in each respective period, were excluded from the computation of basic and diluted net income per common share because their effect is anti-dilutive.

 

For the three and nine months ended September 30, 2018, a total of 2,500,000 common shares and 1,875,000 common shares from warrants issuable upon conversion of outstanding related party convertible notes were excluded from the computation of diluted net income per share because their effect would have been antidilutive.

 

6

 

 

A reconciliation of the shares used in the calculation of basic and diluted earnings (loss) per common share is as follows:  

 

   Three Months Ended   Three Months Ended 
   September 30, 2019   September 30, 2018 
   Income(Loss)   Shares   Per Share   Income(Loss)   Shares   Per Share 
   (Numerator)   (Denominator)   Amount   (Numerator)   (Denominator)   Amount 
Basic Income (Loss) Per Share:                        
Net Income (Loss)  $(293,675)   13,735,177   $(0.02)  $306,715    13,627,888   $0.02 
Effect of dilutive securities:   -    -    -    -    -    - 
Convertible Notes   -    -    -    -    -    - 
Accrued Interest on Convertible Notes   -    -    -    -    -    - 
Warrants   -    -    -    -    -    - 
Stock Options   -    -    -    -    365,037    - 
Diluted Income (Loss) Per Share:  $(293,675)   13,735,177   $(0.02)  $306,715    13,992,925   $0.02 

 

   Nine Months Ended   Nine Months Ended 
   September 30, 2019   September 30, 2018 
   Income(Loss)   Shares   Per Share   Income(Loss)   Shares   Per Share 
   (Numerator)   (Denominator)   Amount   (Numerator)   (Denominator)   Amount 
Basic Income (Loss) Per Share:                        
Net Income (Loss)  $(671,021)   13,658,808   $(0.05)  $584,981    13,541,331   $0.04 
Effect of dilutive securities:   -    -    -    -    -    - 
Convertible Notes   -    -    -    -    -    - 
Accrued Interest on Convertible Notes   -    -    -    -    -    - 
Warrants   -    -    -    -    -    - 
Stock Options   -    -    -    -    380,285    - 
Diluted Income (Loss) Per Share:  $(671,021)   13,658,808   $(0.05)  $584,981    13,921,616   $0.04 

 

Stock-Based Compensation

 

Stock-based compensation expense is estimated at the grant date based on the fair value of the award. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The fair value of restricted stock units granted is based on the closing market price of the Company’s common stock on the date of the grant. The fair value of these awards, adjusted for estimated forfeitures, is amortized over the requisite service period of the award, which is generally the vesting period.

 

Recently Adopted Accounting Standards

 

In February 2016, the FASB created Topic 842 and issued ASU 2016-02, Leases (Topic 842), which created new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases.

 

The Company adopted the requirements of the new standard effective January 1, 2019, using the modified retrospective transition method, which applies the provisions of the standard at the effective date without adjustment to the comparative periods presented.  The Company adopted the following practical expedients and elected the following accounting policies related to this standard:

 

7

 

 

·Carry forward of historical lease classifications and accounting treatment;
·Short-term lease accounting policy election allowing lessees to not recognize right-of-use assets and liabilities for leases with a term of 12 months or less; and
·The option to not separate lease and non-lease components for certain equipment lease categories such as office printers and copiers. 

 

Adoption of this standard had no effect on the consolidated balance sheet as of January 1, 2019, and therefore, did not materially impact operating results or liquidity.  The Company signed an amended lease on its facility effective June 1, 2019, and recognized a lease right-of-use asset and corresponding lease liability of $0.8 million at June 1, 2019. Disclosures related to the amount, timing and uncertainty of cash flows arising from this lease are included in Note 7. 

 

NOTE 2 – REVENUE

 

The Company’s revenues are comprised of product sales as well as products and services provided under long-term government contracts with its customers. All revenue is recognized when the Company satisfies its performance obligation(s) under the contract (either implicit or explicit) by transferring the promised product or service to its customer either when (or as) its customer obtains control of the product or service. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer. A contract’s transaction price is allocated to each distinct performance obligation. The majority of the Company’s contracts have a single performance obligation, as the promise to transfer products or services is not separately identifiable from other promises in the contract and, therefore, not distinct. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation using the Company’s best estimate of a standalone selling price for each distinct product or service in the contract, which is generally based on an observable price.

 

Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or providing services. As such, revenue is recorded net of returns, allowances, customer discounts, and incentives. Sales, value add, and other taxes collected from customers and remitted to governmental authorities are accounted for on a net (excluded from revenues) basis. Shipping and handling costs are included in cost of goods sold.

 

The Company’s performance obligations under long-term government contracts are generally satisfied over time. Revenue from products or services transferred to customers under these performance obligations accounted for approximately 3.8% and 5.3% of revenue for the nine months ended September 30, 2019 and 2018, respectively. This revenue is generally recognized using an input measure based upon the proportion of actual costs incurred to estimated total project costs, which is a method used to best depict the Company’s performance to date under the terms of the contract.

 

Accounting for these long-term government contracts involves the use of various techniques to estimate total revenue and costs. The Company estimates profit on these long-term government contracts as the difference between total estimated revenue and expected costs to complete a contract and recognizes that profit over the life of the contract. Contract estimates are based on various assumptions to project the outcome of future events that may span several years. These assumptions include, among other things, labor productivity, costs and availability of materials, and timing of funding by the U.S. government. The nature of these long-term agreements may give rise to several types of variable consideration, such as claims, awards and incentive fees. Historically, these amounts of variable consideration are not considered significant. Additionally, contract estimates may include additional revenue for submitted contract modifications if there exists an enforceable right to the modification, the amount can be reasonably estimated and its realization is probable. These estimates are based on historical collection experience, anticipated performance, and the Company’s best judgement at the time. These amounts are generally included in the contract’s transaction price and are allocated over the remaining performance obligations. Changes in judgments on these above estimates could impact the timing and amount of revenue recognized with a resulting impact on the timing and amount of associated income. Under these long-term government contracts, the Company may receive payments from customers based upon contractual billing schedules; accounts receivable are recorded when the right to consideration becomes unconditional. In the event a contract loss becomes known, the entire amount of the estimated loss is recognized in the Consolidated Statements of Operations.

 

The majority of the Company’s revenue is from products and services transferred to customers at a point in time and was approximately 96.2% and 94.7% of revenue for the nine months ended September 30, 2019 and 2018, respectively. The Company recognizes revenue at the point in time in which the customer obtains control of the product or service, which is generally when product title passes to the customer upon shipment. In limited cases, title does not transfer and revenue is not recognized until the customer has received the products at its physical location.

 

8

 

 

 

 

The following table summarizes the Company’s sales by market area:

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2019   2018   2019   2018 
Aerospace & Defense  $749,225   $522,471   $2,768,786   $1,947,759 
Process Control & Metrology   950,248    1,349,598    3,064,590    4,463,700 
Laser Systems   361,817    324,115    971,089    1,202,034 
Scientific / R&D   162,461    592,679    639,969    1,201,274 
Total  $2,223,751   $2,788,863   $7,444,434   $8,814,767 

 

Net sales by timing of transfers of goods and services is as follows:

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2019   2018   2019   2018 
Transfer at point in time  $2,148,170   $2,630,850   $7,161,704   $8,350,606 
Transfer over time   75,581    158,013    282,730    464,161 
Total net sales  $2,223,751   $2,788,863   $7,444,434   $8,814,767 

 

The timing of revenue recognition, billings and cash collections results in billed receivables, costs in excess of billings (contract assets), and billings in excess of costs (contract liabilities, previously deferred revenue) on the Consolidated Balance Sheet. Contract liabilities also include customer advances or prepayments. Costs in excess of billings and billings in excess of costs associated with long-term government contracts were not significant at September 30, 2019 or 2018. At September 30, 2019 and 2018, the remaining revenue to be recognized from the long-term government contracts was $29,000 and $386,000, respectively.

 

On September 30, 2019, the Company had approximately $5.4 million of performance obligations, which is also referred to as backlog. Approximately 2.3% of the September 30, 2019 backlog is related to projects that will extend beyond September 30, 2020.

 

NOTE 3 - EQUITY COMPENSATION PROGRAM AND STOCK BASED COMPENSATION

 

a) Stock Option Expense

 

The Company's results of operations for the three months ended September 30, 2019 and 2018, include stock-based compensation expense for stock option grants totaling $35,031 and $27,192, respectively. The Company's results of operations for the nine months ended September 30, 2019 and 2018, include stock-based compensation expense for stock option grants totaling $97,750 and $53,192, respectively. The following table shows the amounts for stock-based compensation included in cost of sales and selling, general and administrative expense for the three and nine months ended September 30, 2019 and 2018:

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2019   2018   2019   2018 
Cost of sales  $9,492   $7,599   $27,211   $14,695 
Selling, general and administrative   25,539    19,593    70,539    38,497 
Total stock-based compensation expense  $35,031   $27,192   $97,750   $53,192 

 

As of September 30, 2019 and 2018, there were $231,066 and $207,725 of unrecognized compensation cost, net of estimated forfeitures, related to non-vested stock options, which are expected to be recognized over a weighted average period of approximately 1.96 years and 1.7 years, respectively.

 

There were 200,000 and 175,000 stock options granted during the nine months ended September 30, 2019 and 2018 respectively. The following range of weighted-average assumptions were used to determine the fair value of stock option grants during the nine months ended September 30, 2019 and 2018:

 

9

 

   Nine months Ended 
   September 30, 
   2019   2018 
Expected Dividend yield   -%   -%
Expected Volatility   125.13%   140.00%
Risk-free interest rate   2.83%   2.60%
Expected term   10 years    10 years 

 

b) Stock Option Activity

 

The following table represents stock options granted, exercised and forfeited during the nine months ended September 30, 2019:

 

       Weighted   Weighted     
       Average   Average     
       Exercise   Remaining   Aggregate 
   Number of   Price per   Contractual   Intrinsic 
Stock Options  Options   Option   Term (years)   Value 
Outstanding January 1, 2019   1,058,208   $0.64    5.58   $337,997 
Granted   200,000    0.79           
Exercised   -                
Expired/Forfeited   (49,841)   1.20           
Outstanding September 30, 2019   1,208,367   $0.61    6.79   $1,222,620 
                     
Exercisable at September 30, 2019   836,698   $0.57    4.92   $769,655 

 

The following table represents non-vested stock options granted, vested and forfeited for the nine months ended September 30, 2019:

 

   Weighted-average 
   Grant-date Fair Value 
   Options   ($) 
Non-Vested - January 1, 2019   349,491    0.74 
Granted   200,000    0.76 
Vested   (172,822)   0.63 
Forfeited   (5,000)   0.79 
Non-Vested - September 30, 2019   371,669    0.80 

 

NOTE 4 - STOCKHOLDERS’ EQUITY

 

The Company approved a matching contribution to participants in the Inrad Optics 401k Plan (the “Plan”) for the year ended December 31, 2018, in February 2019. Cash in the amount of $31,196 and 98,189 common shares of Inrad Optics, Inc. were contributed to the Plan in the second quarter of 2019.

 

NOTE 5 – RELATED PARTY TRANSACTIONS

 

On April 12, 2018, the maturity dates of a $1,500,000 Subordinated Convertible Promissory Note to Clarex Limited (“Clarex”) and a $1,000,000 Subordinated Convertible Promissory Note to an affiliate of Clarex were each extended to April 1, 2021 from April 1, 2018. The notes bear interest at an annual rate of 6%. Interest accrues yearly and is payable on maturity. Unpaid interest, along with principal, may be converted into securities of the Company as follows: the notes are convertible in the aggregate into 1,500,000 units and 1,000,000 units, respectively, with each unit consisting of one share of common stock and one warrant. Each warrant allows the holder to acquire 0.75 shares of common stock at a price of $1.35 per share. As part of the agreement, the expiration dates of the warrants were extended from April 1, 2022 to April 1, 2024. As of September 30, 2019, the Company had accrued interest in the amount of $75,000 associated with these notes.

 

10

 

NOTE 6 – OTHER LONG TERM NOTES

 

Other Long Term Notes consist of the following:

 

   September 30,   December 31, 
   2019   2018 
   (in thousands) 
U.S. Small Business Administration term note payable in equal monthly installments of $1,922 and bearing an interest rate of 4.0% and expiring in July 2029.  $187   $258 
Less current portion   (13)   (13)
Long-term debt, excluding current portion  $174   $245 

 

NOTE 7 – LEASE AMENDMENT

 

The Company entered into an amendment and extension of its building lease on July 8, 2019, retroactive to June 1, 2019. Under the guidance of ASU 2016-02, Leases (Topic 842), the Company determines if such an arrangement contains a lease and whether that lease meets the classification criteria of a finance or operating lease at inception of the arrangement.  The Company determined that this lease is an operating lease and presented as a right-of-use lease asset, short term lease liability and long term lease liability on the consolidated balance sheet.  These assets and liabilities are recognized at the commencement date based on the present value of remaining lease payments over the lease term using the Company’s incremental borrowing rate.

 

Lease expense is recognized on a straight-line basis over the lease term and is included in cost of sales and general and administrative expenses on the consolidated statement of operations. 

 

An initial right-of-use asset of $0.8 million was recognized as a non-cash asset addition with the signing of the July 8, 2019, lease amendment. Cash paid for amounts included in the present value of operating lease liability was $0.1 million during the nine months ended September 30, 2019, and is included in operating cash flows.     

 

Operating lease costs were $0.1 million and $0.2 million during the three and nine months ended September 30, 2019. 

 

The following table presents information about the amount and timing of cash flows arising from the Company’s operating lease as of September 30, 2019:

 

Maturity of Lease Liability  (in thousands) 
2019 (Remaining)  $77 
2020   306 
2021   306 
2022   128 
Total undiscounted operating lease payments   817 
      
Less: imputed interest   (62)
Present value of operating lease liability  $755 
      
Other Information     
Remaining lease term (in months)   32 
Discount rate for operating leases   5.80%

 

11

 

ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Caution Regarding Forward Looking Statements

 

This Quarterly Report contains forward-looking statements as that term is defined in the federal securities laws. The Company wishes to insure that any forward-looking statements are accompanied by meaningful cautionary statements in order to comply with the terms of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. The events described in the forward-looking statements contained in this Quarterly Report may not occur. Generally, these statements relate to business plans or strategies, projected or anticipated benefits or other consequences of the Company’s plans or strategies, projected or anticipated benefits of acquisitions made by the Company, projections involving anticipated revenues, earnings, or other aspects of the Company’s operating results. The words “may,” “will,” “expect,” “believe,” “anticipate,” “project,” “plan,” “intend,” “estimate,” and “continue,” and their opposites and similar expressions are intended to identify forward-looking statements. The Company cautions you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks, and other influences, many of which are beyond the Company’s control, that may influence the accuracy of the statements and the projections upon which the statements are based. Factors which may affect the Company’s results include, but are not limited to, the risks and uncertainties discussed in Items 1A, 7 and 7A of the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the Securities and Exchange Commission on April 1, 2019. Any one or more of these uncertainties, risks, and other influences could materially affect the Company’s results of operations and whether forward-looking statements made by the Company ultimately prove to be accurate. Readers are further cautioned that the Company’s financial results can vary from quarter to quarter, and the financial results for any period may not necessarily be indicative of future results. The foregoing is not intended to be an exhaustive list of all factors that could cause actual results to differ materially from those expressed in forward-looking statements made by the Company. The Company’s actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward looking statements, whether from new information, future events, or otherwise.

 

Critical Accounting Policies and Estimates

 

Our significant accounting policies are described in Note 1 of the accompanying condensed consolidated financial statements and further discussed in our annual financial statements included in our annual report on Form 10-K for the year ended December 31, 2018. In preparing our unaudited condensed consolidated financial statements, we made estimates and judgments that affect the results of our operations and the value of assets and liabilities we report. These include estimates used in evaluating intangibles for impairment such as market multiples used in determining the fair value of reporting units, discount rates applicable in determining net present values of future cash flows, projections of future sales, earnings and cash flow and capital expenditures. It also includes estimates about the amount and timing of future taxable income in determining the Company’s valuation allowance for deferred income tax assets. Our actual results may differ from these estimates under different assumptions or conditions.

 

For additional information regarding our critical accounting policies and estimates, see the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2018.

 

Results of Operations

 

Inrad Optics, Inc.’s business falls into two main categories: Optical Components and Laser Devices/Instrumentation.

 

The Optical Components category is focused on custom optics manufacturing. The Company specializes in high-end precision components. It develops, manufactures and delivers precision custom optics and thin film optical coating services through its Custom and Metal Optics operations. Glass, metal, and crystal substrates are processed using complex processes and techniques to manufacture components, deposit optical thin films, and assemble sub-components used in advanced photonic systems. The majority of custom optical components and optical coating services supplied are used in inspection, process control systems, defense and aerospace electro-optical systems, laser system applications, industrial scanners, and medical system applications.

 

The Laser Devices/Instrumentation category includes the growth and fabrication of crystalline materials with electro-optic (EO) and non-linear optical properties for use in both standard and custom products. This category also includes the manufactured crystal based devices and associated instrumentation. The majority of crystals, crystal components and laser devices manufactured are used in laser systems, defense EO systems, medical lasers and R&D applications by engineers within corporations, universities and national laboratories.

 

12

 

The Company operates a manufacturing facility in Northvale, New Jersey and has its corporate offices in the same location.

 

Revenue

 

Sales for the three months ended September 30, 2019, were $2.2 million, a decrease of 20.3%, or $0.6 million, compared to $2.8 million for the three months ended September 30, 2018. For the nine months ended September 30, 2019, sales were $7.4 million a decrease of 15.5%, or $1.4 million, compared to sales of $8.8 million for the nine month period ending September 30, 2018.

 

Sales to the defense/aerospace market increased by $0.2 million or 43.3% to $0.7 million in the three months ended September 30, 2019, compared to $0.5 million for the three months ended September 30, 2018. For the nine months ending September 30, 2019, sales to the defense/aerospace market increased $0.8 million, or 42.2%, to $2.8 million compared to sales of $1.9 million in the nine month period ending September 30, 2018. The significant increase is mainly attributable to increased demand for our products as military and defense spending has increased over the past year.

 

Process control and metrology (“PC&M”) sales were $1.0 million for the three months ended September 30, 2019, a decrease of $0.4 million, or 29.6%, from $1.4 million for the three months ended September 30, 2018. For the nine months ended September 30, 2019, sales were $3.1 million compared to $4.5 million for the year ago period, a decrease of $1.4 million or 31.3%. The continued reduction in demand for certain products in our PC&M market and the delayed delivery schedules from certain customers, particularly in the semi-conductor industry, has negatively impacted the sales for the three and nine months ended September 30, 2019, compared to September 30, 2018.

 

For the three months ended September 30, 2019, sales to customers in the laser systems market were $0.4 million, an increase of $0.1 million, or 11.6%, from $0.3 million for the three months ended September 30, 2018. For the nine months ended September 30, 2019, sales in the laser systems market were $1.0 million compared to sales of $1.2 million for the nine months ended September 30, 2018, a decline of $0.2 million or 19.2%. The increase in sales for the three months ended September 30, 2019, compared to the three months ended September 30, 2018, was due to increases in shipments to several newer customers. The decrease in sales for the nine months ended September 30, 2019, compared to September 30, 2018, is due to the timing of delivery schedules to an international distributor and one large OEM, partially offset by increases in shipments to several newer customers.

 

Sales to customers in the Scientific/R&D market decreased by $0.4 million, or 72.6%, to $0.2 million for the three months ended September 30, 2019, compared to sales of $0.6 million for the three months ended September 30, 2018. Sales to customers in the Scientific/R&D market for the nine month period ending September 30, 2019, were $0.6 million, compared to $1.2 million, a decrease of $0.6 million or 46.7% for the nine month period ending September 30, 2018. The decrease for the quarter and nine months ending September 30, 2019, compared to the quarter and nine months ending September 30, 2018, is attributable to, in part, reduced revenue on a federal government R&D contract and reduced orders from one national lab.

 

For the three months ended September 30, 2019 and 2018, there were two customers each period that represented 10.0% or more of total sales. For the nine months ended September 30, 2019 and September 30, 2018, there were two customers that represented more than 10.0% of total sales in each period.

 

The Company’s top five customers represented 46.1% of sales in the three month period ended September 30, 2019, compared to 54.5% in the same period in 2018. For the nine month period ended September 30, 2019 and 2018, the Company’s top five customers represented 45.9% and 53.3% of sales, respectively.

 

Orders booked during the first nine months of 2019, totaled $6.7 million, compared to $8.6 million for the same period last year.

 

Order backlog at September 30, 2019 and 2018, was $5.4 million and $6.3 million, respectively. A significant portion of the year-over-year decrease in the order backlog is due to a delay in anticipated orders from several customers in the PC&M and Scientific/R&D markets.

 

Cost of Goods Sold

 

For the three months ended September 30, 2019 and 2018, cost of goods sold was $1.9 million, in each period, or 84.1% and 66.8% of total revenues, respectively. The impact of increased labor and service costs, as well as manufacturing overhead, resulted in an increase in costs of goods sold as a percentage of sales.

 

For the nine months ended September 30, 2019, cost of goods sold were $6.0 million, compared to $6.5 million, a decrease of $0.5 million or 7.1%, compared to the nine month period ending September 30, 2018. The decrease is largely due to the decrease in sales, partially offset by an increase in material costs and labor costs year over year reflecting the mix of sales for the Company’s products. As a percent of total revenues, cost of goods sold for the nine months ended September 30, 2019 and 2018, were 80.6% and 73.3% of total revenues respectively. The increase in cost of goods sold as a percentage of sales reflects the increase in material and labor costs due to the sales mix.

 

13

 

Gross profit for the three months ended September 30, 2019, was $0.4 million or 15.9% of sales, compared to $0.9 million or 33.2% in the same quarter last year. Gross profit for the nine months ended September 30, 2019, was $1.4 million, or 19.4% of sales, compared to $2.4 million or 26.7% of sales, the decline reflecting the reduction in total sales and the impact of the material and labor costs related to the sales mix.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses (“SG&A” expenses) in the three and nine months ended September 30, 2019, amounted to $0.6 million, or 27.3% of sales, and $2.0 million, or 26.9% of sales, compared to $0.6 million, or 20.8% of sales, and $1.6 million, or 18.7% of sales, respectively, for the same period a year ago. The increase in SG&A expenses reflects costs related to recruiting and increased staffing, increased travel and marketing expenses, and other administrative costs for the year to date period.

 

Income (Loss) from Operations

 

The Company incurred a net loss from operations of $0.3 million for the three months ended September 30, 2019, compared with operating income of $0.3 million in the three months ended September 30, 2018. The decrease in income primarily reflects the impact of the Company’s lower sales in the three months ended September 30, 2019, compared to the same period last year, coupled with an increase in the cost of goods sold and SG&A costs. The Company incurred a net loss from operations of $0.6 million for the nine months ended September 30, 2019, compared with operating income of $0.7 million for the nine months ended September 30, 2018. The decrease in operating income for year to date period reflects lower sales, combined an increase in certain SG&A costs.

 

Other Income and Expense

 

There was no significant change in net interest expense for the three months ended September 30, 2019, compared to the same period in 2018, as there was no significant change in the Company’s borrowing level. Net interest expense for the nine months ended September 30, 2019, compared to September 30, 2018, was $116,000 and $119,000, respectively. The decrease represents the lower overall outstanding debt balance.

 

Income Taxes

 

For the three months and nine months ended September 30, 2019, the Company did not record a current provision for either state tax or federal alternative minimum tax due to the losses incurred for both income tax and financial reporting purposes.

 

For the three months and nine months ended September 30, 2018, the Company did not record a current provision for income taxes due to the availability of net operating loss carryforwards to offset taxable income for both federal and state tax purposes.

 

Net Income (Loss)

 

The Company had a net loss of $0.3 million for the three months ended September 30, 2019, compared to a net income of $0.3 million for the three months ended September 30, 2018. The net loss primarily reflects the decrease in sales for the three months ended September 30, 2019, compared to the 2018 period, combined with the increase in costs of goods sold and SG&A expenses. For the nine months ended September 30, 2019, the Company incurred a net loss of $0.7 million, compared with net income of $0.6 million. Lower sales, combined with a less favorable product mix, higher related material costs and higher SG&A costs led to the decrease in net income.

 

Liquidity and Capital Resources

 

The Company’s primary source of liquidity is cash and cash equivalents and on-going collection of accounts receivable. The Company’s major use of cash in recent years has been for financing operations, for payment of accrued and current interest on convertible debt, for servicing of long term debt, and for capital expenditures.

 

As of September 30, 2019 and December 31, 2018, the Company had cash and cash equivalents of $0.8 million and $1.2 million, respectively.

 

The Company occupies approximately 42,000 square feet of space located at 181 Legrand Avenue, Northvale, New Jersey pursuant to a net lease which was amended on July 8, 2019, retroactive to June 1, 2019, for an additional three year term. Under the terms of the lease, the Company is obligated for all real estate taxes, maintenance and operating costs of the facility.

 

14

 

On April 12, 2018, the maturity dates of a $1,500,000 Subordinated Convertible Promissory Note to Clarex Limited (“Clarex”) and a $1,000,000 Subordinated Convertible Promissory Note to an affiliate of Clarex were each extended to April 1, 2021 from April 1, 2019. The notes bear interest at an annual rate of 6%. Interest accrues yearly and is payable on maturity. Unpaid interest, along with principal, may be converted into securities of the Company as follows: the notes are convertible in the aggregate into 1,500,000 units and 1,000,000 units, respectively, with each unit consisting of one share of common stock and one warrant. Each warrant allows the holder to acquire 0.75 shares of common stock at a price of $1.35 per share. As part of the agreement, the expiration dates of the warrants were extended from April 1, 2022 to April 1, 2024. As of September 30, 2019, the Company had accrued interest in the amount of $75,000 associated with these notes.

 

The following table summarizes net cash (used in) operating, investing and financing activities for the nine months ended September 30, 2019 and 2018:

 

   Nine Months Ended 
   September 30, 
   2019   2018 
   (in thousands) 
Net cash provided by (used in) operating activities  $(11)  $230 
Net cash (used in) investing activities   (291)   (131)
Net (used in) financing activities   (71)   (9)
Net (decrease) in cash and cash equivalents  $(373)  $(139)

 

Net cash used in operating activities was $11,000 for the nine months ended September 30, 2019, compared to net cash provided by operations of $230,000 in the same period last year. Net cash used in operating activities in the nine months ended September 30, 2019, resulted primarily from the net loss incurred for the period and a reduction in accounts receivable. The net cash provided by operating activities of $230,000 in the nine months ended September 30, 2018, resulted primarily from operating profits as well as reductions in accounts receivable, reductions in accounts payable and accrued liabilities, and lower contract liabilities.

 

Net cash used in investing activities was $291,000 during the nine months ended September 30, 2019, compared to $131,000 in the same period last year reflecting capital expenditures in both periods. Net cash used in financing activities during the nine months ended September 30, 2019 and 2018, relates to required principal payments.

 

Overall, cash and cash equivalents decreased by $373,000 for the nine months ended September 30, 2019 and increased $90,000 in the 2018 period.

 

Management believes, based on the Company’s operations and its existing working capital resources together with existing cash flows, that the Company has sufficient cash flows to fund operations through at least November 14, 2020.

 

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

The Company is a smaller reporting company and not required to provide the information required under this item.

 

ITEM 4.CONTROLS AND PROCEDURES

 

a.Disclosure Controls and Procedures

 

Our Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) as of September 30, 2019 (the “Evaluation Date”), have concluded that as of the Evaluation Date, our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports we file or submit under the Exchange Act (1) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and (2) is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, as appropriate to allow for timely decisions regarding required disclosure.

 

b.Changes in Internal Controls over Financial Reporting

 

There were no changes in our internal control over financial reporting during the quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

15

 

PART II.OTHER INFORMATION

 

ITEM 1.LEGAL PROCEEDINGS

 

None.

 

ITEM 1A.RISK FACTORS

 

Not applicable

 

ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3.DEFAULTS UNDER SENIOR SECURITIES

 

None.

 

ITEM 4.MINE SAFETY DISCLOSURES

 

Not applicable

 

ITEM 5.OTHER INFORMATION

 

None

 

ITEM 6.EXHIBITS

 

11.An exhibit showing the computation of per-share earnings is omitted because the computation can be clearly determined from the material contained in this Quarterly Report on Form 10-Q.

 

31.1Certificate of the Registrant’s Chief Executive Officer, Amy Eskilson, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

 

31.2Certificate of the Registrant’s Chief Financial Officer, Theresa A. Balog, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

 

32.1Certificate of the Registrant’s Chief Executive Officer, Amy Eskilson, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

 

32.2Certificate of the Registrant’s Chief Financial Officer, Theresa A. Balog, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

 

101.INSXBRL Instance Document*

 

101.SCHXBRL Taxonomy Extension Schema*

 

101.CALXBRL Taxonomy Extension Calculation Linkbase*

 

101.DEFXBRL Taxonomy Extension Definition Linkbase*

 

101.LABXBRL Taxonomy Extension Label Linkbase*

 

101.PREXBRL Taxonomy Extension Presentation Linkbase*

 

*Filed herewith
  
**Furnished herewith

 

16

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    Inrad Optics, Inc.
     
  By: /s/ Amy Eskilson
    Amy Eskilson
    President and Chief Executive Officer
     
  By: /s/ Theresa A. Balog
    Theresa A. Balog
    Chief Financial Officer,
    Secretary and Treasurer
Date: November 14, 2019    

 

17